Subject(s)
Humans , Male , Female , Adult , Middle Aged , Euthanasia/ethics , Euthanasia/legislation & jurisprudence , Euthanasia/trends , Suicide, Assisted , Surveys and Questionnaires , Organic LawABSTRACT
Objetivo: Describir la prevalencia de uso de fármacos anticolinérgicos (FA) en pacientes de edad avanzada que consultan por pérdida cognitiva. Valorar la repercusión cognitiva y funcional de estos fármacos. Pacientes y métodos: Revisión retrospectiva de historias clínicas de pacientes visitados en 2015 y 2016. Se identificaron FA con la Anticholinergic Cognitive Burden Scale. La función cognitiva se exploró mediante el Mini Mental State Examination (MMSE) y la funcional con el índice de Barthel y el índice de Lawton y Brody. Se comparó la diferencia de las puntuaciones de las escalas en un año entre los pacientes expuestos a anticolinérgicos con los no expuestos. Resultados: Muestra de 610 pacientes (edad media=81,1años), 71% mujeres. El 37,2% estaban tomando algún FA. La diferencia media (desviación estándar [DE]) de los expuestos respeto a los no expuestos, el empeoramiento anual en el índice de Barthel, en el índice de Lawton y Brody y en el MMSE fue de −4 (4,5), −0,3 (0,4) y −1 (0,9), respetivamente. Conclusiones: Un tercio de los pacientes que consultan por pérdida cognitiva están tomando algún FA. Los pacientes expuestos muestran una tendencia mayor a empeorar funcionalmente
Objective: Describe the prevalence of the anticholinergic drugs (AD) used in patients who consult in regard to loss of memory. Assess the cognitive and functional repercussion of these drugs. Patients and methods: Retrospective review of the clinic history of the patients who consulted the clinic in 2015 and 2016. We used the Anticholinergic Cognitive Burden Scale. We explored cognition with the Mini Mental State Examination (MMSE) and function with the Barthel Index and the Lawton and Brody Scale. We compared the difference of scale scores between the patients exposed and not exposed to AD. Results: Sample size of 610 patients (mean age=81.1years), 71% female. 37.2% of patients took AD. The mean (SD) difference between exposed and not exposed patients and the year-on-year worsening rate of the Barthel Index and the Lawton and Brody Scale and MMSE were −4 (4.5), −0.3 (0.4) and −1 (0.9), respectively. Conclusions: One third of patients who consulted for cognitive loss are taking AD. Patients exposed to AD show a greater tendency to impairment
Subject(s)
Humans , Male , Female , Aged , Aged, 80 and over , Cognitive Dysfunction/drug therapy , Cholinergic Antagonists/adverse effects , Prevalence , Aged , Cholinergic Antagonists/therapeutic use , Cross-Sectional Studies/methods , Retrospective Studies , Alzheimer DiseaseABSTRACT
OBJECTIVE: Describe the prevalence of the anticholinergic drugs (AD) used in patients who consult in regard to loss of memory. Assess the cognitive and functional repercussion of these drugs. PATIENTS AND METHODS: Retrospective review of the clinic history of the patients who consulted the clinic in 2015 and 2016. We used the Anticholinergic Cognitive Burden Scale. We explored cognition with the Mini Mental State Examination (MMSE) and function with the Barthel Index and the Lawton and Brody Scale. We compared the difference of scale scores between the patients exposed and not exposed to AD. RESULTS: Sample size of 610 patients (mean age=81.1years), 71% female. 37.2% of patients took AD. The mean (SD) difference between exposed and not exposed patients and the year-on-year worsening rate of the Barthel Index and the Lawton and Brody Scale and MMSE were -4 (4.5), -0.3 (0.4) and -1 (0.9), respectively. CONCLUSIONS: One third of patients who consulted for cognitive loss are taking AD. Patients exposed to AD show a greater tendency to impairment.
